Prospecto: information for the user
HEMANGIOL 3.75 mg/ml, oral solution
propranolol
Read this prospect carefully before your child starts taking this medicine, as it contains important information for you.
• Keep this prospect, as you may need to read it again.
• If you have any doubts, consult your doctor or pharmacist.
•This medicine has been prescribed only for your child, and should not be given to other people, even if they have the same symptoms as your child, as it may harm them.
•If your child experiences any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. See section 4.
1. What is HEMANGIOL and for what it is used
2. What you need to know before your child starts taking HEMANGIOL
3. How to give HEMANGIOL to your childa your child
4. Possible adverse effects
5. Storage of HEMANGIOL
6. Contents of the container and additional information
What is HEMANGIOL
The name of your medicine is HEMANGIOL. The active ingredient is propranolol.
Propranolol belongs to a group of medicines known as beta-blockers.
What is it used for
This medicine is used to treat a disease called hemangioma. A hemangioma is an excess of blood vessels that have formed a lump in the skin or beneath it. The hemangioma can be superficial or deep. It is sometimes called a "strawberry mark" because the surface of a hemangioma looks a bit like a strawberry.
Hemangiol is initiated in children who are between 5 weeks and 5 months old, when:
No use HEMANGIOL
If your child:
If you are breastfeeding your child and you are taking medications that should not be used with HEMANGIOL (see “If you are breastfeeding your child” and “Use of HEMANGIOL with other medications”),do not administerthis medication to your child.
Warnings and precautions
Before your child starts taking HEMANGIOL, inform your doctor:
Important signs to look for after administering HEMANGIOL
Hypoglycemia risks
This medication may mask the warning signs of hypoglycemia (also known as low blood sugar levels). It may also worsen hypoglycemia in children, especially during fasting periods (e.g., poor oral intake, infection, vomiting), when glucose demands increase (e.g., cold, stress, infections), or in cases of overdose. These signs may include:
The risk of developing hypoglycemia remains elevated throughout the treatment period.
To avoid hypoglycemia risks,administer HEMANGIOL during or immediately after a meal and avoid administering the last dose near bedtime (see section 3).You must feedsufficiently andfrequently to your child during treatment. If your child does not eat enough, if they have another illness, or if they vomit, it is recommended to omit the dose. DO NOT ADMINISTER HEMANGIOL TO YOUR CHILD UNTIL THEY HAVE EATEN PROPERLY. If your child shows any signs of hypoglycemia while taking HEMANGIOL,interrupt treatment and call your doctor immediately or go to the hospital. If the child is conscious,administer an oral liquid containing sugar. |
Risks of bronchoconstriction
Interrupt treatment and contact a doctor immediately if, after administering HEMANGIOL to your child, you observe the following symptoms indicative of bronchoconstriction (transient restriction of bronchial passages that causes respiratory difficulty): cough, rapid or difficult breathing, or wheezing, associated or not with blue skin discoloration.
Interrupt treatment and contact a doctor immediately if your child has symptoms similar to a cold associated with respiratory difficulty and/or wheezing while takingHEMANGIOL. |
Risk of hypotension and bradycardia (slow heart rate)
HEMANGIOL may reduce blood pressure (hypotension) and heart rate (bradycardia). Therefore, your child should be under close clinical and heart rate monitoring for 2 hours after the first dose and after any dose increase. Subsequently, during treatment, your doctor will perform periodic clinical examinations on your child.
Risk of hyperkalemia
HEMANGIOL may increase blood potassium levels (hyperkalemia). In cases of large ulcerated hemangioma, your child's blood potassium levels should be measured.
If your child is to be administered general anesthesia
Inform your doctor that your child is taking HEMANGIOL. This is because your child may have low blood pressure if certain anesthetics are administered while taking this medication (see “Use of HEMANGIOL with other medications”). It may be necessary to interrupt HEMANGIOL at least 48 hours before anesthesia.
If you are breastfeeding your child
Use of HEMANGIOL with other medications
In particular, if you are breastfeeding your child, inform your doctor or pharmacist if you or your child are taking:
If you have any other questions, consult your doctor or pharmacist.
HEMANGIOL contains sodium and propylene glycol
This medication contains less than 23 mg of sodium (1 mmol) per dose; this is essentially “sodium-free”.
This medication contains 2.08 mg of propylene glycol/kg/day. If the baby is less than 4 weeks old, consult your doctor or pharmacist, especially if the baby has been administered other medications containing propylene glycol or alcohol.
The treatment of your child has been initiated by a doctor with experience in the diagnosis, treatment, and management of infantile hemangioma.
Follow exactly the administration instructions for this medication given to your child by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Never modify the dose you are administering to your child yourself. All dose increases and all weight adjustments for your child must be made by your doctor..
Dose
• The dose is based on your child's weight following the following scheme:
Weeks (daily dose) | Dose per administration | Hours of administration |
First week (1 mg/kg/day) | 0.5 mg/kg | •one in the morning •one at last hour of the afternoon•minimum interval of 9 hours between the two administrations |
Second week (2 mg/kg/day) | 1mg/kg | |
Third and subsequent weeks (3 mg/kg/day) | 1.5 mg/kg |
.
•When necessary, you can dilute the medication in a small amount of infant formula or apple and/or orange juice adapted to the child's age, and administer it to your child in a bottle. Do not mix the medication directly with a full bottle of milk or juice.
For children weighing up to 5 kg, you can mix the dose with a teaspoon of infant formula (approximately 5 ml). For children weighing more than 5 kg, you can mix the dose with a tablespoon of infant formula or fruit juice (approximately 15 ml).
Use the mixture within 2 hours of preparation.
How to administer HEMANGIOL to your child
Usage instructions:
• Step 1. Remove the different elements from the case
The case contains the followingelementsthat you will need to administer the medication:
- The glass bottle containing 120 ml of oral solution of propranolol.
- The oral syringe dosifier in mg that comes with this medication.
Remove the bottle and the oral syringe from the case, and take the syringe out of the plastic bag.
• Step 2. Check the dose
Check the dose of HEMANGIOL in milligrams (mg) as prescribed by your doctor.
Locate this number on the oral syringe.
• Step 3. Open the bottle
The bottle has a child-resistant cap. This is how to open it: press the plastic cap down while turning the cap counterclockwise (to the left).
Do not shake the bottle before use.
• Step 4. Insert the syringe
Insert the tip of the oral syringe into the bottle in a vertical position, and push the plunger all the way.
Do not remove the adapter from the syringe's mouth.
Use only the oral syringe provided with the medication to measure and administer the dose. Do not use a spoon or any other dispenser.
• Step 5: Extract the dose
With the oral syringe in place, turn the bottle upside down. Pull the plunger of the syringe until the number of mg needed is reached.
•Step 6: Check for air bubbles
If you see air bubbles in the syringe, hold the syringe vertically, push the plunger up enough to expel all large air bubbles, and adjust it to the prescribed dose by the doctor.
• Step 7. Extract the syringe
Turn the bottle to a vertical position, and separate the syringe from the bottle. Be careful not to push the plunger during this step.
• Step 8. Close the bottle
Put the plastic cap back on the bottle by turning it clockwise (to the right).
• Step 9. Administer HEMANGIOL to your child
Insert the syringe into your child's mouth and place it in the inner cheek.
Now you can slowly expel HEMANGIOL from the syringe directly into your child's mouth.
Do not put the child to bed immediately after administering the medication.
• Step 10: Clean the syringe.
Do not disassemble the syringe. Clean the empty syringe in a clean glass of water after each use:
1- Take a clean glass of water
2- Pull the plunger to the end
3- Pour the water down the sink
4-Repeat this cleaning process 3 times.
Do not use any soap or alcohol-based product to clean it. Dry the exterior with a cloth. Do not insert the syringe into a sterilizer or dishwasher.
Store the bottle and syringe together in the case until the next use, in a safe place where the child cannot see or reach it. Dispose of the syringe when the bottle is finished.
If you administer more HEMANGIOL to your child than you should
If you have administered more HEMANGIOL to your child than you should, consult your doctor immediately.
If you forget to administer HEMANGIOL to your child
Omit the missed dose, and do not administer a double dose to compensate for the missed doses. Continue treatment at the usual frequency. One dose in the morning and one in the afternoon.
If you interrupt your child's treatment with HEMANGIOL
HEMANGIOL may be discontinued suddenly at the end of treatment, as decided by the doctor.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Additionally, after administration of HEMANGIOL, important warning signs of possible side effects such as low blood pressure, low heart rate, low blood sugar concentration, or bronchospasm (difficulty breathing) should be sought. See section 2 of this prospectus.
Side effectsvery frequent (can affect more than 1 in 10 people):
• bronchitis (inflammation of the bronchi),
• sleep disorders (insomnia, poor quality sleep, and difficulty waking up),
• diarrhea and vomiting.
Side effectscommon (can affect up to 1 in 10 people):
• bronchospasm (respiratory difficulty),
•bronchiolitis (inflammation of small bronchi with respiratory difficulty and wheezing in the chest, associated with cough and fever),
• decreased blood pressure,
• decreased appetite,
• agitation, nightmares, irritability,
• drowsiness,
• cold extremities,
• constipation, abdominal pain,
• erythema (cutaneous erythema).
• Diaper dermatitis.
Side effectsinfrequent (can affect up to 1 in 100 people):
• conduction or cardiac rhythm disorders (slow or irregular heartbeats),
• urticaria (skin allergic reaction), alopecia (hair loss),
• decreased blood sugar concentration,
• reduction in the number of leukocytes (white blood cells in the blood).
The frequency of the following side effects isunknown (cannot be estimated from available data)
Communication of side effects
If your child experiences any type of side effect, consult your doctor or pharmacist, even if it is a side effect that does not appear in this prospectus. You can also report them directly through the national notification system included in theAppendix V. Mediante thecommunication of side effects you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the label of the bottle. The expiration date is the last day of the month indicated.
Store the bottle in the outer packaging to protect it from light. Store the bottle and oral syringe in the case between each use. Do not freeze.
After the first opening of the bottle, the medication must be used within a maximum period of 2 months.
Medicines should not be thrown down the drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This way, you will help protect the environment.
Composition of HEMANGIOL
Appearance of HEMANGIOL and contents of the container
Marketing Authorization Holder
PIERRE FABRE MEDICAMENT
Les Cauquillous
81500 Lavaur
FRANCE
Responsible for manufacturing
FARMEA
10 rue Bouché Thomas
ZAC Sud d’Orgemont
49000 ANGERS
FRANCE
O
PIERRE FABRE MEDICAMENT PRODUCTION
Site PROGIPHARM, Rue du Lycée
45500 GIEN
FRANCE
You can request more information about this medication by contacting the local representative of the marketing authorization holder.
Last review date of this leaflet:
The detailed information about this medication is available on the website of the European Medicines Agency: http://www.ema.europa.eu .
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.